Clinical Trials Logo

Clinical Trial Summary

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04321031
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date June 15, 2020
Completion date February 21, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT01045499 - LAGB as a Treatment for Morbid Obesity in Adolescents N/A
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Not yet recruiting NCT05495139 - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease N/A
Completed NCT04988204 - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04369521 - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Enrolling by invitation NCT00983463 - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting NCT00658164 - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Phase 3
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT06441409 - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT01735799 - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS N/A
Completed NCT01446276 - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease N/A
Completed NCT00930384 - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis N/A
Recruiting NCT02469272 - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Phase 1
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Completed NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Phase 2
Terminated NCT01355575 - Rifaximin in Fatty Liver Disease Phase 4
Completed NCT01210989 - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis N/A